This appeal is from a decision of the United States Patent and Trademark Office (PTO) Board of Appeals (board) affirming the examiner’s rejection of claims 1-6 “as being improper Markush claims [1] and misjoinder under 35 USC 121.”[2] The board also dismissed, for want of jurisdiction, the appeal of claims 8-13, 16, 17, 20, 22 and 23 in that the claims “were withdrawn from *456consideration since they were directed to non-elected inventions.” We reverse and remand.
Invention
The invention relates to cyclic diamine derivatives which possess the common property of psychotherapeutic effectiveness. The derivatives are identified by a single generic formula expressed in Markush format in representative claim 1:
1. A compound having the genera! formula
R, Ri — C — N ~/N — Y — R, II \ / X (CH.) .
A) an at least mononuclear heterocyclic group having 4 to 10 carbon atoms in the ring system bound to the group —C—N through a carbon atom and containing at
X
least one oxygen, nitrogen or sulphur atom,
B) substitution products of A) containing at least one substituent selected from the group consisting of halogen, trifluoromethyl, hydroxy, alkoxy of 1 to 3 carbon atoms, unsubstituted amino, amino substituted by up to two alkyl ' groups each having 1 to 3 carbon atoms and alkyl groups having 1 to 6 carbon atoms,
X is oxygen, sulphur or an NH-group,
Y is an alkylcne group having 1 to 3 carbon atoms in the chain, or an alkylene group having 1 to 3 carbon atoms in the chain substituted by a) up to 3 alkyl groups each having up to 3 carbon atoms and a total of not more than 8 carbon atoms, or b) substituted by one or two phenyl groups,
R, is selected from the group consisting of
C) an at least mononuclear carbocyclie or heterocyclic group having 4 to 10 carbon atoms in the ring system, containing but one heteroatom in a ring,
D) substitution products of C) containing at least one substituent selected from the group consisting of nitro, halogen, trifluoromethyl, alkyl having 1 to 6 carbon atoms, hydroxy, alkoxy having 1 to 3 carbon atoms, unsubstituted amino groups and amino groups substituted by up to two alkyl groups each having 1-3 carbon atoms,
R, is hydrogen or up to two substituents selected from alkyl groups having up to 2 carbon atoms and phenyl groups;
n is 2 or 3.
Background
In the first office action dated January 17, 1974, the examiner “objected” to claims 1-6, 8-13 and 23 and required applicants to elect one of three groups of claims: group I (claims 7 and 14-22), group II (claims 8-13), or group III (claim 23). Applicants elected, with traverse, group I and brought to the examiner’s attention his failure to include claims 1-6 in the groups. The status of claims 1-6 was clarified in the second and final action, dated December 26, 1974, in which those claims were “rejected.” The examiner also stated that claim 1 embraced 24 enumerated independent and distinct inventions. The examiner, in conclusion, stated that:
Markush claims 1 to 6 are rejected as being improper Markush claims and for misjoinder under 35 U.S.C. 121. (922 O.G. 1016, 4th and 6th paragraph).3
*457In his Answer, the examiner expanded upon the basis of the rejection. He discussed MPEP 808, in particular the phrase “independent and distinct” of § 121 and applied the phrase to the claims. Continuing, the examiner discussed the Markush claims and stated:
The compounds embraced do not have a common nucleus and are improperly Markushed under the criteria set forth in M.P.E.P. 706.03(y) * * *.4 * * * The specification discloses that certain .compounds have activities not shared by all of the scope claimed * * *.
At the outset, the board decided that § 121 was an adequate legal basis for the examiner to reject a single claim “embracing” more than one independent and distinct invention. In support thereof, the board incorporated two board decisions5 which discussed the interrelated rejections of “misjoinder under 35 U.S.C. 121” and “as being improper Markush claims” as applied here. The board analyzed the claims in light of those decisions and found them to contain multiple independent and distinct inventions.
Appellants argue before this Court that each of the claims is directed to but a single invention and § 121 is not a proper ground for rejection in any event.
*458OPINION
The board affirmed the examiner’s rejection of claims 1-6 “as being improper Markush claims and misjoinder under 35 U.S.C. 121.” However, the reasoning of the board shows that the analysis of the “improper Markush claims” rejection was to be supportive of the rejection under § 121 rather than alternative to it. We have jurisdiction over both rejections,6 but since the Markush rejection is inextricably intertwined with the § 121 rejection, we make no decision on the propriety of the Markush rejection and remand to the board for its consideration. However, the result of any such consideration must be consistent with our analysis of an applicant’s rights under the second paragraph of 35 U.S.C. § 112.
An applicant is given, by the statute, the right to claim his invention with the limitations he regards as necessary to circumscribe that invention, with the proviso that the application comply with the requirements of § 112. We have decided in the past that § 112, second paragraph, which says in part “[t]he specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention,” allows the inventor to claim the invention as he contemplates it. In re Wolfram, 486 F.2d 588, 179 USPQ 620 (CCPA 1973).
As a general proposition, an applicant has a right to have each claim examined on the merits. If an applicant submits a number of claims, it may well be that pursuant to a proper restriction requirement, those claims will be dispersed to a number of applications. Such action would not affect the right of the applicant eventually to have each of the claims examined in the form he considers to best define his invention. If, however, a single claim is required to be divided up and presented in several applications, that claim would never be considered on its merits. The totality of the resulting fragmentary claims would not necessarily be the equivalent of the original claim. Further, since the subgenera would be defined by the examiner rather than by the applicant, it is not inconceivable that a number of the fragments would not be described in the specification.7
It is apparent that § 121 provides the Commissioner with the authority to promulgate rules designed to restrict an application to one of several claimed inventions when those inventions are found to be “independent and distinct.” It does not, however, provide a basis for an examiner acting under the authority of the Commissioner to reject a particular claim on that same basis.
Even though the statute allows the applicant to claim his invention as he sees fit, it is recognized that the PTO must have some means for controlling such administrative matters as examiner caseloads and the amount of searching done per filing fee.8 But, in drawing priorities between *459the Commissioner as administrator and the applicant as beneficiary of his statutory rights, we conclude that the statutory rights are paramount. We hold that a rejection under § 121 violates the basic right of the applicant to claim his invention as he chooses.
Appellants contend that the examiner’s action in withdrawing claims 8-13, 16, 17, 20, 22 and 23 from consideration as drawn to nonelected inventions constitutes a rejection under the holding of In re Haas, 486 F.2d 1053, 179 USPQ 623 (CCPA 1973), and, therefore, the board improperly found a lack of jurisdiction. We do not agree. Clearly our decision in In re Hengehold, 58 CCPA 1099, 440 F.2d 1395, 169 USPQ 473 (1971), disposed of the theory that a restriction requirement and the subsequent action of the examiner in withdrawing nonelected claims from consideration,9 per se, constitutes a rejection. An exception is found in In re Haas, supra, wherein we determined that the examiner’s action in withdrawing claims was a rejection because the “claims were withdrawn from consideration not only in this application but prospectively in any subsequent application because of their content.” 486 F.2d at 1056, 179 USPQ at 625. (Emphasis ours.) We do not understand the PTO to make such a holding with respect to claims 8-13,16, 17, 20, 22 and 23, nor that appellants argue that the PTO does so. Indeed, we note that appellants admitted in their brief before the board that claims 8-13 and 23 were “properly withdrawable.” Consequently, the board’s dismissal of the appeal to claims 8-13 and 23 was correct. The Commissioner’s brief admits that claims 16,17, 20 and 22 contain species of the invention of generic claim 1 and would be provided an examination on the merits should the § 121 rejection be reversed. We remand for appropriate action on claims 16,17, 20 and 22, and dismiss the appeal of claims 8-13 and 23 for lack of jurisdiction.
The decision of the board affirming the rejection under § 121 is reversed, and the case is remanded for consideration of the “improper Markush” rejection of claims 1-6 and appropriate action on claims 16, 17, 20 and 22. The appeal of claims 8-13 and 23 is dismissed for lack of jurisdiction.
REVERSED AND REMANDED.
. Section 706.03(y) (note 4, infra) of the Manual of Patent Examining Procedure (MPEP) provides guidance in the use of Markush format and is cited by the examiner in his Answer before the board. MPEP 803 (note 3, infra), which applies 35 U.S.C. § 121 to Markush claims, is also cited by the examiner in his final office action.
. Section 121 provides, in pertinent part:
Divisional applications
If two or more independent and distinct inventions are claimed in one application, the *456Commissioner may require the application to' be restricted to one of the inventions. If the other invention is made the subject of a divisional application which complies with the requirements of section 120 of this title it shall be entitled to the benefit of the filing date of the original application.
. The examiner exercised his discretion under 922 O.G. 1016 which was a notice issued by the Commissioner on May 1, 1974, (now MPEP 803) which provides in part:
A Markush-type claim is directed to “independent and distinct inventions,” if two or more of its members are so unrelated and diverse that a prior art reference anticipating the claim with respect to one of the members would not render the claim obvious under 35 U.S.C. 103 with respect to the other member(s).
[Paragraph 4.]
If the claim is of that nature, the examiner is authorized to reject it as an improper Markush claim and for misjoinder under 35 U.S.C. 121 and to require the applicant to restrict the application to a single invention. In making such a requirement, the examiner will (1) clearly delineate the members or groups of members believed to constitute improperly joined inventions, and (2) state reasons fully explaining why they are independent and distinct. Applicant’s response to such a requirement should be an election of a single adequately disclosed and supported invention, with or without restriction of the claim(s) to that invention. Of course, the response must not introduce new matter into the application. See 35 U.S.C. 132 and In re Welstead, 59 CCPA 1105, 463 F.2d 1110, 174 USPQ 449 (1972). A refusal to elect a single invention will be treated as a non-responsive reply.
If the members of the Markush group are sufficiently few in number or so closely related that a search and examination of the en*457tire claim can be made without serious burden, the examiner is encouraged to examine it on the merits, even though it is directed to independent and distinct inventions. In such a case, the examiner will not follow the procedure outlined in the preceding paragraph and will not require restriction.
[Paragraph 6.]
Where the examiner has rejected the claim and required restriction and the applicant has responded without restricting the claim(s) to a single invention, the examiner shall, if the position is adhered to, again reject the claim and any other Markush claims not restricted to the elected invention. No further examination of these claims is required unless and until such rejection has been overcome. However, if the search of the single elected invention develops prior art which would render both the elected invention and the improper Markush claim(s) unpatentable, such prior art may be applied in rejections of both without a complete search of the subject matter of the improper Markush claim(s). Otherwise, only true generic claims and those restricted to the elected invention will be examined in the usual manner.
[Paragraph present in MPEP 803 deleted.]
Review of the rejection will be by appeal to the Board of Appeals under 35 U.S.C. 134.
. MPEP 706.03(y) provides, in pertinent part:
Ex parte Markush, 1925 C.D. 126; 340 O.G. 839, sanctions, in chemical cases, claiming a genus expressed as a group consisting of certain specified materials. This type of claim is employed when there is no commonly accepted generic expression which is commensurate in scope with the field which the applicant desires to cover. * * *
* * * * * *
Where a Markush expression is applied only to a portion of a chemical compound, the propriety of the grouping is determined by a consideration of the compound as a whole, and does not depend on there being a community of properties in the members of the Markush expression.
When materials recited in a claim are so related as to constitute a proper Markush group, they may be recited in the conventional manner, or alternatively. For example, if “wherein R is a material selected from the group consisting of A, B, C and D” is a proper limitation then “wherein R is A, B, C or D” shall also be considered proper.
. The board incorporated both Ex parte Dorlars, Appeal No. 148-56, decided May 2, 1975, reproduced in the record, and Ex parte Haas, 188 USPQ 374 (Bd.App.1975). The board stated in Dorlars that:
What we do find relevant is the single question: does the Examiner have legal authority to attack the propriety of an individual claim, whether of the Markush-type or otherwise, which includes a plurality of independent and distinct inventions? We think clearly the answer is “yes.”
The board based its conclusion in Dorlars on § 121 and further stated:
Clearly the mere fact that review of decisions requiring restriction within a single claim is available under 35 USC 134, whereas decisions requiring restriction between claims are not, cannot serve to limit application of the statute. That relates only to the issue of jurisdiction to review; it has no bearing on the scope of the statute itself — on the scope of authority conferred.
In Ex parte Haas, the board decided that Rule 141, 37 CFR 1.141 regards an allowable generic claim as one that does not include more than one independent and distinct invention. The board decided that § 121 is a legal basis for rejecting a single claim as an improper Markush claim.
. 37 CFR 1.196(a) provides that in decisions of the board:
The affirmance of the rejection of a claim on any of the grounds specified constitutes a general affirmance of the decision of the primary examiner on that claim, except as to any ground specifically reversed.
See also In re Sichert, 566 F.2d 1154, 1164, 196 USPQ 209, 217 (CCPA 1977).
. See Fields v. Conover, 58 CCPA 1366, 443 F.2d 1386, 170 USPQ 276 (1971), wherein a subgenus was not described and In re Ruschig, 54 CCPA 1551, 379 F.2d 990, 154 USPQ 118 (1967), wherein a species of a properly described genus was found not to be described.
. We take notice of a practice formerly utilized by the PTO and found in the MPEP:
705 Patentability Reports
Where an application, properly assigned to one examining group, is found to contain one or more claims per se classifiable in one or more other groups, which claims are not divisible inter se or from the claims which govern classification of the application in the first group, the application may be referred to the other group or groups concerned for a report as to the patentability of certain designated claims. This report will be known as a Patentability Report (P.R.) and will be signed by the primary examiner in the reporting group.
The report, if legibly written, need not be typed.
*459Note that the Patentability Report practice is suspended, except in extraordinary circumstances. See § 705.01(e).
We further note the authority of the Commissioner under 35 U.S.C. § 41(b) to “establish charges for * * * services furnished by the Patent and Trademark Office.”
. 37 CFR 1.142(b) provides: